Skip to main content
NAMS logo

NAMS

NewAmsterdam Pharma Co N.V.
$36.99 +2.09 (+5.99%) At close · Jul 7
Market Cap
$4.32B
Shares
116,903,979

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.99 Open$35.36 Day$34.27–37.37 52W$19.22–42.21 Avg vol 30d1.2M Short int9.2M · 7.8% float · 7.3d Short vol44% Last earningsMay 7, 2026 DataFeb 2021–Jul 2026 Filing10-Q · May 7
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.1 · calm Equity put/call 0.69
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +12%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 77%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +17%
trailing
6-month return +13%
trailing
YTD return +5%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $33 › 200d $34 — 200d above 50d
Institutional flow Distributing
4 of 171 funds reported for Jun 30 · net -178 sh shares · +1 new
Insider flow Distributing
Net -$2.3M over 90 days · 100% sells
Short interest Rising
7.85% of float · ▲ +13.2% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
171 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth −51%
Y/Y
EPS growth +33%
Y/Y
Balance sheet $490.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −31%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
77% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $33 › 200d $34 — 200d above 50d
Institutional flow Distributing
4 of 171 funds reported for Jun 30 · net -178 sh shares · +1 new
Insider flow Distributing
Net -$2.3M over 90 days · 100% sells
Short interest Rising
7.85% of float · ▲ +13.2% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
171 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $19 Now $37 · 77% 52-wk high $42
vs 200-day avg +10% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $728.9M FY2025

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NAMS
NewAmsterdam Pharma Co N.V.
this stock
$4.32B +5.4% -50.6% 7.8%
ONC
BeOne Medicines Ltd.
$446.53B +1.7% +22179.2% 908.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$132.55B +15.2% +46.2% 31.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$70.90B -12.3% +20.8% 16.5 3.2%
ARGX
Argenx SE
$57.49B +9.4% 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
171
% held
106.3%
Reported
4 of 171
Top holder
Frazier Life Sciences Man…
Held Float
View
Held by Funds
Fund positions
27
View
Short & Settlement
Short Interest Rising
Shares short
9.2M
Days to cover
7.3d
Change
+1.1M sh
View
Short Volume
Short vol %
44%
As of
Jul 7, 2026
Short Total
View
Fails to Deliver
FTD shares
35.7K
Value
$1.1M
As of
Jun 10, 2026
View
Off-Exchange
Off-exchange %
52.7%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.3M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$22.5M
Net income (FY)
$-203.0M
EPS diluted
$-1.72
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
11
View
Proposed Sales
Value
$1.4M
Shares
44.6K
Filed
Mar 11, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View
Investor Relations
Latest news
NewAmsterdam Pharma Reports Induc…
Published
Jul 2, 2026
View

Performance

5D 20D 120D MTD YTD
NAMS +9.2% +17.4% +13.2% +9.2% +5.4%
SPY +0.9% +1.4% +7.6% +0.1% +9.7%
vs SPY +8.3% +16.0% +5.6% +9.0% -4.2%
Key facts CIK 1936258 CUSIP N62509109 13F (30d) 5 filings 4 filers Visit website Investor relations